Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2019
Price :
$35
*
At a glance
- Drugs Atuzaginstat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Cortexyme
- 07 Dec 2019 According to a Cortexyme media release, data from this study were presented at the 2019 Clinical Trials in Alzheimer Disease (CTAD) meeting, which is being held December 4-7, 2019 in San Diego.
- 07 Dec 2019 Results published in the Cortexyme Media Release
- 17 Jul 2019 According to a Cortexyme media release, data from the study has been presented at Alzheimers Association International Conference 2019.